Cell Reports, Volume 26

Supplemental Information

Human Pluripotent Stem Cell-Derived Multipotent

Vascular Progenitors of the Mesothelium Lineage

Have Utility in Tissue Engineering and Repair

Thomas Colunga, Miranda Hayworth, Sebastian Kreß, David M. Reynolds, Luoman Chen, Kristopher L. Nazor, Johannes Baur, Amar M. Singh, Jeanne F. Loring, Marco Metzger, and Stephen Dalton




Figure S1. Related to Figure 1.

(A) hESC-derived (WA09) splanchnic mesoderm (SplM) cells generated after 4 days of culture in CDM supplemented with Wnt3a (25 ng/ml) and BMP4 (100 ng/ml) were fixed and stained with antibodies for ISL1, NKX2.5 and FLK1. Scale bars, 50 µm.

(**B**) Immunofluorescence analysis of K3 hiPSCs and hESCs (TE03, WA07 and WA01) cultured and stained as in (**A**). Nuclei were counter stained with DAPI. Scale bars, 50 µm.

(C) qRT-PCR data showing fold-change of transcript levels for pluripotency markers (*NANOG*, *OCT4* and *SOX2*) in SplM and MesoTs relative to hESCs. TaqMan assays for each transcript were performed in


technical triplicate and fold-change shown relative to hESCs (WA09) after normalization with 18S RNA. **(D)** Flow cytometry data of untreated hESCs (WA09), SplM, and MesoT showing the absence of the pluripotent marker SOX2 (left plot) and presence of lineage specific marker ISL1 (middle plot) in SplM. As cells transition to MesoT, ISL1 is downregulated (right plot).

(E) Immunofluorescence of WA07, TE03 and K3 hiPSC lines after differentiation of SplM to MesoT followed by probing with WT1 and TBX18 antibodies. Nuclei were counter stained with DAPI. Scale bar, 50 μm.

(F) Flow cytometry pseudocolor plot of MesoT cells probed with antibodies for WT1 and TBX18.

(G) WA09-derived MesoT cells were fixed and probed with antibodies for lineage specific markers WT1 and TBX18. Nuclei were counterstained with DAPI. Right hand side is a magnification of the insets from left. Scale bars, 50 µm.

Error bars ± standard deviation.



	2 4 M 20		
		1 . C	the star and
		10 0	

 α SMA

MesoT

Figure S2. Related to Figure 1.

(A) Schematic showing the progression of splanchnic mesoderm (SplM) to mesothelium-like cells (MLCs) and then MesoTs. Removal and addition of growth factors and inhibitors are indicated above the arrows for each stage.

(B) qRT-PCR data showing fold-change of transcript levels for pluripotency (*OCT4, NANOG*), SplM (*ISL1* and *NKX2.5*) and mesothelium (*WT1, TBX18, TCF21 and MSLN*). TaqMan assays for each transcript were performed in technical triplicate and fold-change shown relative to untreated hESCs (WA09) after normalization with 18S RNA.

(C) Immunofluorescence analysis of MLCs and MesoTs directly derived from MLCs. After EMT induction of MLCs (A), cells become migratory but retain expression of mesothelial lineage markers. Cells were fixed and stained with antibodies against ISL1, NKX2.5, WT1, TBX18, E-cadherin (epithelial marker) and alpha smooth muscle actin (α SMA). Scale bars, 50 μ m. Error bars ± standard deviation.




Figure S3. Related to Figure 2.

(A) Heatmap showing the relationship between cell type-specific DNA methylation modules (WA09 hPSCs, hPSC-derived splanchnic mesoderm, MesoTs and hPSC-derived cardiomyocytes). Module 9 comprises 1846 cytosines and is characteristic of MesoTs.

(B) Heatmap showing highly enriched H3K27ac (blue) lineage specific sites in hESC-derived cardiomyocytes (CM) and the absence of H3K4me1 in corresponding sites for MesoT. (C and D) Gene Ontology analysis of genes analyzed in Figure 2D.




Figure S4. Related to Figures 3 and 4.

(A) Cells numbers at different stages of differentiation are shown. Cell number was counted at each stage after plating 1 million hESCs (WA09).

(B) Immunofluorescence of MesoT cells probed with lineage specific antibodies for mesothelium (WT1), smooth muscle (calponin, MYH11), endothelium (vWF), or fibroblasts (DDR2). Nuclei were counterstained with DAPI. Scale bar, 50 µm.


(C) MesoT-derived Fibroblasts on day 12 were probed with antibodies for WT1, DDR2, calponin and counterstained with DAPI. Scale bar, 50 μ m.


(D) Contraction assays as for Figure 3 except performed on WA09 hESCs. Contraction is shown as the % change in cell surface area for individual cells. Each treatment group was compared to corresponding control time point to determine statistical significance. N=20.

(E) Flow cytometry histograms of MesoT cells probed with antibodies for CD31 (endothelium), NG2 (pericyte), and isotype control.

(F) Immunofluorescence of MesoT (FBS) cells after culturing with 2% FBS +VEGF (endothelium) or +PDGF-BB (SMC). Cells were fixed and probed with antibodies against vWF or MYH11 and counter stained with DAPI. Scale bars, 50 μ m.

(G) Magnified images shown in Figure 3J. Scale bar, 100 µm.








Figure S5. Related to Figure 5.

(A) Whole mount image of a mechanically injured heart 5 days after resecting part of the ventricle.(B) DiO labeled MesoT human cells (green) were applied immediately after resection and attached to injured area. Micron bar, 1 mm.

(C) Immunohistochemistry image showing the absence of hGolgi⁺ cells in the repair zone of neonatal hearts that did not receive MesoT cells following mechanical injury. The section was also probed with antibodies for a-smooth muscle actin (aSMA), CD31 and counterstained with DAPI. Scale bar, 50 μ m. (D) Blood vessel from Figure 5D showing the presence of erythrocytes due to autofluorescence. Scale bar, 20 μ m.




Figure S6. Related to Figure 6.

(A) Basic bioreactor design showing media vessels, pump, pressure sensors, and the inflow/outflow ports that circulate perfused media through the vascular bed.

(B) MTT assay of a decellularized construct showing the absence of viable cells.

(C) Left panel; bright field image before FITC-dextran perfusion. Time lapse images 5 and 25 seconds after FITC-dextran perfusion into decellularized scaffolds seeded at low density with MesoTs. Scale bar, 100 μ m.

(**D** and **E**) Light sheet microscopy images as in Figure 6J showing $CD31^+$ endothelium lining recellularized jejunal scaffolds after 28 days. Scale bars, 500 μ m.

(F) Light sheet microscopy image showing NG2⁺ pericytes lining MesoT-seeded vessels. Scale bar, 150 μ m.

(G) Gross anatomy image as in Figure 6L after harvesting of anastomosed tissue.

Antibody	Application	Supplier	Identifier
Goat Polyclonal anti-Islet-1	**		Cat#AF1837;
	IF	R&D systems	RRID:AB_2126324
Mouse Monoclonal anti-Nkx2.5 (Clone	IF	R&D Systems	Cat#MAB2444;
259416)	11'	K&D Systems	RRID:AB_2151378
Goat Polyclonal anti-E-cadherin	IF	R&D Systems	Cat#AF648;
	11 ²	Red Systems	RRID:AB_355504
Mouse Monoclonal anti-TBX18 (Clone	IF	R&D Systems	Cat#MAB63371;
635305)		-	RRID:AB_10892533
Rabbit Polyclonal anti-Flk1-1	IF	Acris Antibodies	Cat# AP02618PU-S;
		GmbH Santa Cruz	RRID:AB_1624459
Goat Polyclonal anti-SOX2 (Clone Y-17)	IF	Biotechnology	Cat#sc-17320; RRID:AB 2286684
Mouse Monoclonal anti-ZO-1 (Clone 1)			Cat#610966;
Wouse Wonoeronar anti-20-1 (Crone 1)	IF	BD Biosciences	RRID:AB 398279
		Santa Cruz	Cat#sc-7555;
Goat Polyclonal anti-DDR2 (N-20)	IF	Biotechnology	RRID:AB 639054
	IF	Sigma-Aldrich	Cat#C2687;
Mouse Monoclonal anti-Calponin	IF		RRID:AB_476840
Mouse Monoclonal anti-smooth muscle		Abcam	Cat#ab683;
Myosin heavy chain 11 antibody (Clone	IF		RRID:AB 2235569
1G12)			—
Rabbit Polyclonal anti-von Willebrand	IF	Dako	Cat#A0082;
Factor		2 with	RRID:AB_2315602
Rabbit Monoclonal anti-Wilms Tumor	IF, IHC	Abcam	Cat#ab89901;
Protein (Clone CAN-R9(IHC)-56-2)	,		RRID:AB_2043201
Mouse Monoclonal anti-alpha Smooth Muscle Actin (Clone 1A4)	IF, IHC	Abcam	Cat#ab7817; RRID:AB 262054
Rabbit Polyclonal anti-alpha Smooth			Cat#ab5694;
Muscle Actin	IF, IHC	Abcam	RRID:AB 2223021
Rabbit Monoclonal anti-Vimentin (Clone	IF, IHC	Abcam	Cat#ab92547;
EPR3776)			RRID:AB 10562134
Mouse Monoclonal anti-CD31 (Clone	IF, IHC	Dako	Cat#M0823;
JC70A)			RRID:AB 2114471
Mouse Monoclonal anti-NG2		Abcam	Cat#ab83508;
Mouse Monocional anti-NG2	IF, IHC		RRID:AB_2087616
Donkey Polyclonal anti-Mouse IgG	IF, IHC	Thermo Fisher	Cat#:A21202;
(H+L) Alexa Fluor 488 Conjugated	II, IIIC	Thermo Tisher	RRID:AB_141607
Donkey Polyclonal anti-Rabbit IgG (H+L)	IF, IHC	Thermo Fisher	Cat#A21206;
Alexa Fluor 488 Conjugated	,		RRID:AB_141708
Donkey Polyclonal anti-Goat IgG (H+L)	IF, IHC	Thermo Fisher	Cat#A21432;
Alexa Fluor 555 Conjugated			RRID:AB_141788
Donkey Polyclonal anti-Mouse IgG (H+L) Alexa Fluor 555 Conjugated	IF, IHC	Thermo Fisher	Cat#A31570; RRID:AB_2536180
Donkey Polyclonal anti-Rabbit IgG (H+L)	IF, IHC	Thermo Fisher	Cat#A31572;
Alexa Fluor 555 Conjugated			RRID:AB 162543
Donkey Polyclonal anti-Goat IgG (H+L)	IF, IHC	Thermo Fisher	Cat#A21447;
Alexa Fluor 647 Conjugated			RRID:AB 141844
Donkey Polyclonal anti-Rabbit IgG (H+L)	IF, IHC	Thermo Fisher	Cat#A31573;
Alexa Fluor 647 Conjugated			RRID:AB 2536183
Donkey Polyclonal anti-Sheep IgG (H+L)	IHC	Thermo Fisher	Cat#A21448;
Alexa Fluor 647 Conjugated			RRID:AB_2535865

Table S2 List of Antibodies. Related to STAR Methods.

KRID:AB_2118291
Key: IF – immunofluorescence, IHC – immunohistochemistry, FC – flow cytometry, ChIP – chromatin immunoprecipitation

Gene	Supplier	Identifier	Chromosome Location
POU5F1/OCT4	Thermo Fisher	Hs04260367_gH	Chr.6: 31164337 - 31170693
SOX2	Thermo Fisher	Hs01053049_s1	Chr.3: 181711924 - 181714436
NANOG	Thermo Fisher	Hs02387400_g1	Chr.12: 7789396 - 7796061
ISL1	Thermo Fisher	Hs00158126_m1	Chr.5: 51383124 - 51394730
NKX2.5	Thermo Fisher	Hs00231763_m1	Chr.5: 173232104 - 173235312
GATA4	Thermo Fisher	Hs00171403_m1	Chr.8: 11676919 - 11760002
WT1	Thermo Fisher	Hs01103751_m1	Chr.11: 32387775 - 32435535
TBX18	Thermo Fisher	Hs01385457_m1	Chr.6: 84666834 - 84764236
TCF21	Thermo Fisher	Hs00162646_m1	Chr.6: 133889121 - 133895537
MSLN	Thermo Fisher	Hs00245879_m1	Chr.16: 760746 - 768865
RNA18S5	Thermo Fisher	Hs03928985_g1	Chr.Un NT_167214: 109078 - 110946

Table S3 Taqman Primers for qRT-PCR. Related to STAR Methods.